Trabectedin is a marine natural product, approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer. Clinical and experimental evidence indicates that trabectedin is particularly effective against myxoid liposarcomas where response is associated to regression of capillary networks. Here, we investigated the mechanism of the antiangiogenic activity of trabectedin in myxoid liposarcomas. Trabectedin directly targeted endothelial cells, impairing functions relying on extracellular matrix remodeling (invasion and branching morphogenesis) through the upregulation of the inhibitors of matrix metalloproteinases TIMP-1 and TIMP-2. Increased TIMPs synthesis by the tumor microenvironment following trabectedin treatment was confirmed in xenograft models of myxoid liposarcoma. In addition, trabectedin upregulated tumor cell expression of the endogenous inhibitor thrombospondin-1 (TSP-1, a key regulator of angiogenesis-dependent dormancy in sarcoma), in in vivo models of myxoid liposarcomas, in vitro cell lines and primary cell cultures from patients' myxoid liposarcomas. Chromatin Immunoprecipitation analysis showed that trabectedin displaced the master regulator of adipogenesis C/EBP from the TSP-1 promoter, indicating an association between the up-regulation of TSP-1 and induction of adipocytic differentiation program by trabectedin. We conclude that trabectedin inhibits angiogenesis through multiple mechanisms, including directly affecting endothelial cells in the tumor microenvironmentwith a potentially widespread activityand targeting tumor cells' angiogenic activity, linked to a tumor-specific molecular alteration. What's New? Trabectedin is a natural product approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer. While the response of myxoid liposarcoma to trabectedin is characteristically associated with vessel regression, the underlying mechanisms remain unclear. In this study, trabectedin showed antiangiogenic activity linked to the upregulation of endogenous inhibitors of angiogenesis: endothelial cell-derived TIMP-1 and TIMP-2 and tumor cell-derived TSP-1, the latter associated with adipocytic differentiation. Such connection between differentiation and angiogenesis in myxoid liposarcoma sets the basis for new combination therapies, and points to TIMP-1, TIMP-2 and TSP-1 as potential markers of tumor response to trabectedin.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1

D'Incalci M;
2015

Abstract

Trabectedin is a marine natural product, approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer. Clinical and experimental evidence indicates that trabectedin is particularly effective against myxoid liposarcomas where response is associated to regression of capillary networks. Here, we investigated the mechanism of the antiangiogenic activity of trabectedin in myxoid liposarcomas. Trabectedin directly targeted endothelial cells, impairing functions relying on extracellular matrix remodeling (invasion and branching morphogenesis) through the upregulation of the inhibitors of matrix metalloproteinases TIMP-1 and TIMP-2. Increased TIMPs synthesis by the tumor microenvironment following trabectedin treatment was confirmed in xenograft models of myxoid liposarcoma. In addition, trabectedin upregulated tumor cell expression of the endogenous inhibitor thrombospondin-1 (TSP-1, a key regulator of angiogenesis-dependent dormancy in sarcoma), in in vivo models of myxoid liposarcomas, in vitro cell lines and primary cell cultures from patients' myxoid liposarcomas. Chromatin Immunoprecipitation analysis showed that trabectedin displaced the master regulator of adipogenesis C/EBP from the TSP-1 promoter, indicating an association between the up-regulation of TSP-1 and induction of adipocytic differentiation program by trabectedin. We conclude that trabectedin inhibits angiogenesis through multiple mechanisms, including directly affecting endothelial cells in the tumor microenvironmentwith a potentially widespread activityand targeting tumor cells' angiogenic activity, linked to a tumor-specific molecular alteration. What's New? Trabectedin is a natural product approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer. While the response of myxoid liposarcoma to trabectedin is characteristically associated with vessel regression, the underlying mechanisms remain unclear. In this study, trabectedin showed antiangiogenic activity linked to the upregulation of endogenous inhibitors of angiogenesis: endothelial cell-derived TIMP-1 and TIMP-2 and tumor cell-derived TSP-1, the latter associated with adipocytic differentiation. Such connection between differentiation and angiogenesis in myxoid liposarcoma sets the basis for new combination therapies, and points to TIMP-1, TIMP-2 and TSP-1 as potential markers of tumor response to trabectedin.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/67441
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 42
social impact